October Bio-Health Exports in Numbers
According to the October trade figures released by the Ministry of Trade, Industry and Resources on November 1, Korea's bio-health exports reached USD 1.53 billion in October. That is 30.2% higher than the same month a year earlier and the highest October total on record. The government pointed to two drivers:
It helps to separate two stories in these numbers. Multi-year CMO contracts mostly benefit a few companies with large-scale capacity. The expansion into Latin America is different: it is a route that SMEs making finished drugs, biosimilars and medical devices can also use.
Why Latin America — Market Structure and Entry Routes
Public procurement led by Brazil and Mexico
Brazil and Mexico are the region's largest markets. In both countries, public health systems buy a large share of products. As a result, tender pricing and reliable supply matter as much as the product itself.
Fast-track review based on reference-country approvals
Brazil's ANVISA and Mexico's COFEPRIS have both introduced or expanded reliance pathways that consider approvals from trusted regulators such as the US FDA and the EMA. Whether a product already has US or EU approval can strongly affect how quickly it reaches the market. However, eligible products, recognized reference authorities and filing requirements change often. Always check the latest regulations immediately before filing.
A local registration holder is the first hurdle
In both countries, applications are filed in the name of a local entity or registration holder. A foreign manufacturer will find it hard to hold the approval directly. That makes choosing a partner the first real regulatory decision.
Key Preparation for ANVISA and COFEPRIS
Export Contracts and Supply Risk
Government Support and a Step-by-Step Plan
Available support includes KHIDI's (Korea Health Industry Development Institute) bio-health global expansion programs, help with overseas certification and export costs through programs such as the Export Voucher, and support for overseas regulatory consulting. Each program has its own eligibility rules, co-payment ratio and eligible cost items, so always check the requirements in each call for applications.
Approvals in Latin America can take years, so starting early pays off. KITIM supports the full process, from building an overseas regulatory strategy to preparing applications for KHIDI and export support programs. If you are considering Brazil or Mexico, contact KITIM for an initial assessment of each product's entry potential and the support programs you can use.
